<DOC>
	<DOCNO>NCT00884715</DOCNO>
	<brief_summary>Evaluate pharmacokinetics , safety efficacy octreotide implant treatment symptom carcinoid syndrome .</brief_summary>
	<brief_title>Pharmacokinetics , Efficacy Safety Octreotide Implant Patients With Carcinoid Syndrome</brief_title>
	<detailed_description>This study evaluate longer act octreotide formulation . A subcutaneous implant 2 dos evaluate pharmacodynamics , efficacy safety period 9 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>histologically confirm tumor document evidence carcinoid syndrome life expectancy least 6 month previous positive octreotide scan receive stable dos octreotide injection performance status 02 ECOG performance scale poorly differentiate high grade neuroendocrine tumor significant cv , hepatic , renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>